Matthew K. Szot, Chief Financial Officer at Cadrenal Therapeutics, Inc. (CVKD), sold 12,400 shares at $14.05 ($174K) on 2025-09-25, disclosed to the SEC on 2025-09-26.
Scheduled sale ($174k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.00 | 1,500 | $21K | 12.1% |
| 2 | $14.05 | 10,900 | $153K | 87.9% |
| Total | $14.04 avg | 12,400 | $174K | 100% |
| Filing → |
| SNES | SELL | 2025-11-17 | $3 | — | Filing → |
| CVKD | SELL | 2025-10-28 | $50K | — | Filing → |
| CVKD | SELL | 2025-10-14 | $49K | — | Filing → |